Andrew T. Kaplan
Andrew T. Kaplan's purchase track record
Andrew T. Kaplan has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/20/2026 | KLRA | $134.38M | -27.2% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
SGRY Volumes Soften as Analysts Debate Valuation. Surgery Partners is experiencing lower trading volumes while analysts continue to debate its value. Recent reports note a significant five-year decline, yet some estimates suggest the stock is still below fair value. The company remains a point of interest within the Russell 2000, with mixed views on its competitive position and future challenges.
Transaction History
| KLRA | ▼ Sell | Other | 17,857,143 | — | 4/20/2026 | View on chart |
| KLRA | ▲ Buy | Open Market | 8,398,438 | $134.4M | 4/20/2026 | View on chart |
| SGRY | ▼ Sell | Open Market | 7,826,870 | $261.7M | 12/19/2023 | View on chart |
| SGRY | ▼ Sell | Other | 474,407 | $0 | 12/19/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Kailera Therapeutics faces scrutiny on weight loss differentiation
Recent analysis highlights the need for Kailera to clearly differentiate its weight loss drug from existing GLP-1 competitors. The stock is currently trading near its support level, reflecting cautious sentiment as investors await concrete progress on the company's obesity treatment pipeline.
Kailera Therapeutics faces scrutiny on weight loss differentiation. Recent analysis highlights the need for Kailera to clearly differentiate its weight loss drug from existing GLP-1 competitors. The stock is currently trading near its support level, reflecting cautious sentiment as investors await concrete progress on the company's obesity treatment pipeline.